文献速递乳腺MR乳腺X线

整合MRI与乳腺X线摄影的双模态虚拟活检系统用于无创预测乳腺癌HER2状态

Dual-Modality Virtual Biopsy System Integrating MRI and MG for Noninvasive Predicting HER2 Status in Breast Cancer.
PubMed 文献 · Acad Radiol · 2025-03-10

研究开发并验证基于深度学习的决策可视化生物标志物系统(DM-VBS),利用MRI放射组学特征和乳腺X线摄影深度学习特征预测乳腺癌HER2状态。550例患者分为训练、内部验证和外部验证队列,系统对HER2零表达、低表达和阳性患者的平均准确率分别为85.42%、80.4%和89.68%。病灶大小、病灶数量、强化类型和微钙化等影像特征在不同HER2状态间存在显著差异,但HER2零表达与低表达组间除外。

要点

  • DM-VBS对HER2零表达、低表达和阳性患者的平均准确率分别为85.42%、80.4%和89.68%。
  • 区分HER2零/低表达与阳性时,MRI放射组学模型和乳腺X线摄影深度学习模型的AUC分别为0.800-0.850。
  • 区分HER2零表达与低/阳性时,两模型AUC分别为0.793-0.847。

核心结论

  • DM-VBS可预测HER2状态并辅助临床医生制定乳腺癌治疗决策。

研究设计与样本

  • 研究从MRI提取放射组学特征、从乳腺X线摄影提取深度学习特征,构建四个子模型并整合为XGBoost模型进行HER2状态三分类,使用癌症影像档案库的两个独立数据集验证,共550例患者分为训练、内部验证和外部验证队列。

关键影像表现/征象

  • 病灶大小、病灶数量、强化类型和微钙化在不同HER2状态间存在显著差异,但HER2零表达与低表达组间无显著差异。

诊断标准与关键数值

  • 模型I(MRI放射组学)和模型III(乳腺X线摄影深度学习)区分HER2零/低表达与阳性病例的AUC为0.800-0.850。
  • 模型II(MRI放射组学)和模型IV(乳腺X线摄影深度学习)区分HER2零表达与低/阳性病例的AUC为0.793-0.847。
  • DM-VBS在验证队列中对HER2零表达、低表达和阳性患者的平均准确率分别为85.42%、80.4%和89.68%。

临床应用与阅片要点

  • DM-VBS可预测HER2状态并辅助临床医生制定乳腺癌治疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Accurate determination of human epidermal growth factor receptor 2 (HER2) expression is critical for guiding targeted therapy in breast cancer. This study aimed to develop and validate a deep learning (DL)-based decision-making visual biomarker system (DM-VBS) for predicting HER2 status using radiomics and DL features derived from magnetic resonance imaging (MRI) and mammography (MG).

MATERIALS AND METHODS: Radiomics features were extracted from MRI, and DL features were derived from MG. Four submodels were constructed: Model I (MRI-radiomics) and Model III (mammography-DL) for distinguishing HER2-zero/low from HER2-positive cases, and Model II (MRI-radiomics) and Model IV (mammography-DL) for differentiating HER2-zero from HER2-low/positive cases. These submodels were integrated into a XGBoost model for ternary classification of HER2 status. Radiologists assessed imaging features associated with HER2 expression, and model performance was validated using two independent datasets from The Cancer Image Archive.

RESULTS: A total of 550 patients were divided into training, internal validation, and external validation cohorts. Models I and III achieved an area under the curve (AUC) of 0.800-0.850 for distinguishing HER2-zero/low from HER2-positive cases, while Models II and IV demonstrated AUC values of 0.793-0.847 for differentiating HER2-zero from HER2-low/positive cases. The DM-VBS achieved average accuracy of 85.42%, 80.4%, and 89.68% for HER2-zero, -low, and -positive patients in the validation cohorts, respectively. Imaging features such as lesion size, number of lesions, enhancement type, and microcalcifications significantly differed across HER2 statuses, except between HER2-zero and -low groups.

CONCLUSION: DM-VBS can predict HER2 status and assist clinicians in making treatment decisions for breast cancer.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wang Q, Zhang ZQ, Huang CC, et al. Dual-Modality Virtual Biopsy System Integrating MRI and MG for Noninvasive Predicting HER2 Status in Breast Cancer. Acad Radiol. 2025. PMID: 40068996. doi:10.1016/j.acra.2025.02.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。